Literature DB >> 10765600

[Evaluation of the hormonal replace therapy (HRT) effect on generation of reactive oxygen intermediates (ROI) by neutrophil in peripheral blood of menopausal women].

M P Pertyńska1, H Tchórzewski, P Lewkowicz, J Paśnik, T Pertyński.   

Abstract

UNLABELLED: About 30% of women population in Poland is already in the perimenopausal age. HRT (hormonal replacement therapy) is the best way of diminishing the unfavorable symptoms of this state.
AIM OF STUDY: The effect of HRT on ROI production by neutrophils before and after HRT, to determinate it's antioxidative influence on cells. MATERIAL: We have examined 40 women both from the Dept. of Menopausal Disease in the Research Institute Polish Mother's Memorial Hospital (RIPMMH) and Out Patient Menopausal Clinic of RIPMMH with average age of 49.8; between October 1997 and January 1998.
METHODS: We determined ROI generation by luminol-enhanced chemiluminescence, using standard stimuli like fLMP, PMA and OZ. We used Luminometer 1251, manufactured by Pharmacia-LKB. For statistic evaluation Fisher test, Kolmogorow-Smirnow test and T-student test were used.
RESULTS: We found that estrogen-progestagen therapy had a suppressive effect on generation of ROI by neutrophils in vitro and in vivo after using receptor dependent and non-dependent stimuli. ROI generation by neutrophils of peripheral blood induced by PMA, a receptor dependent stimuli, is diminished, both, after HRT or as an effect of estrogen-progestagen action in vitro. The results suggest direct inhibition effect on the neutrophil ability to ROI generation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10765600

Source DB:  PubMed          Journal:  Ginekol Pol        ISSN: 0017-0011            Impact factor:   1.232


  1 in total

1.  Influence of hormone supplementation therapy on the incidence of denture stomatitis and on chemiluminescent activity of polymorphonuclear granulocytes in blood of menopausal-aged women.

Authors:  Magdalena Golecka-Bakowska; E Mierzwinska-Nastalska; M Bychawska
Journal:  Eur J Med Res       Date:  2010-11-04       Impact factor: 2.175

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.